Medexus Pharmaceuticals Schedules First Quarter Fiscal 2021 Conference Call
August 05 2020 - 8:30AM
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”)
(TSXV: MDP, OTCQX: PDDPF) today announced that it plans to
host a conference call at 8:00 AM Eastern Time on Wednesday, August
12, 2020 to discuss the Company’s financial results for the fiscal
2021 first quarter ended June 30, 2020, as well as the Company’s
corporate progress and other developments. The Company expects to
file its financial statements along with its MD&A post market
on August 11, 2020.
The conference call will be available via
telephone by dialing toll free 844-602-0380 for Canadian and U.S.
callers or +1 862-298-0970 for international callers, or on the
Company’s Investor Events section of the website:
https://www.medexus.com/en_US/news-media/events .
A webcast replay will be available on the
Company’s Investor Events section of the website
(https://www.medexus.com/en_US/news-media/events ) through November
12, 2020. A telephone replay of the call will be available
approximately one hour following the call, through August 19, 2020,
and can be accessed by dialing 877-481-4010 for Canadian and U.S.
callers or +1 919-882-2331 for international callers and entering
conference ID: 36502.
About Medexus Pharmaceuticals
Inc.
Medexus is a leading specialty pharmaceutical
company with a strong North American commercial platform. The
Company’s vision is to provide the best healthcare products to
healthcare professionals and patients, through our core values of
Quality, Innovation, Customer Service and Teamwork. Medexus
Pharmaceuticals is focused on the therapeutic areas of auto-immune
disease, hematology and allergy. The Company’s leading products
are: Rasuvo™ and Metoject®, a unique formulation of methotrexate
(auto-pen and pre-filled syringe) designed to treat rheumatoid
arthritis and other auto-immune diseases; IXINITY®, an intravenous
recombinant factor IX therapeutic for use in patients 12 years of
age or older with Hemophilia B – a hereditary bleeding disorder
characterized by a deficiency of clotting factor IX in the blood,
which is necessary to control bleeding; and Rupall®, an innovative
prescription allergy medication with a unique mode of action.
For more information, please
contact:
Ken d’Entremont, Chief Executive OfficerMedexus
Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:
ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus
Pharmaceuticals Inc.Tel.: 514-762-2626 ext. 202E-mail:
roland.boivin@medexus.com
Investor Relations
(U.S.):Crescendo Communications, LLCTel:
+1-212-671-1020Email: mdp@crescendo-ir.com
Investor Relations
(Canada):Frank CandidoDirect Financial Strategies
and Communication Inc.Tel: 514-969-5530E-mail:
frank.candido@medexus.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2023 to Jul 2024